Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of aflibercept plus FOLFIRI in First-Line Metastatic Colorectal Cancer
2013-004081-33Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jun 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aflibercept in metastatic colon cancer (mCRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 6 months. Started Jun 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2013-004081-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004081-33.